Free · no account · quoted from the filing

What changed in AMGN's 10-Q

Source: 10-Q filed 2026-05-01 · compared against 10-Q 2025-11-05. Every passage below is quoted verbatim from the filing itself.

Legal

This filing

In March 2026, Sanofi SA, Regeneron Pharmaceuticals, Inc. (Regeneron) and Amgen entered into a settlement agreement that resolved the following Repatha patent litigations

Tariffs and Trade Policy

This filing

In April 2026, the Administration issued a proclamation imposing Section 232 tariffs... However, in December 2025, in recognition of our capital investments in U.S. manufacturing, we received relief from Section 232 tariffs for approximately the next three years.

Pipeline

This filing

a statistically significant and clinically meaningful 77% proptosis response rate

Product Listing

This filing

Our principal products are Repatha, Prolia, EVENITY, TEPEZZA, Otezla, BLINCYTO, Nplate, XGEVA, TEZSPIRE, KYPROLIS, ENBREL, Aranesp, Vectibix, UPLIZNA, IMDELLTRA/IMDYLLTRA and KRYSTEXXA.

Risk Factors Disclosure

This filing

CMS has selected ENBREL and Otezla for Medicare price setting beginning in 2026 and 2027

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel, plus 1 further change without a quotable passage — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.